Korea United Pharm Inc. (033270.KS) Stock

033270.KS logo

Korea United Pharm Inc.

033270.KSSouth Korea
Healthcare

Company profile

Korea United Pharm reported revenue of 288.76 billion KRW for fiscal year 2025, about flat from fiscal year 2024, and net income of 38.31 billion KRW. That is a net profit margin of 13.3% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 73.82 billion KRW, up 3.5% from a year before. In Q1 2026 it reported net income of 13.98 billion KRW, against net income of 12.66 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 278.94 billion KRW in fiscal year 2023 to 288.76 billion KRW in fiscal year 2025, 1.7% a year on average.

What stands out

  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Korea United Pharm Inc.

Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to approximately 40 countries. Korea United Pharm Inc. was founded in 1987 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Won-Ho Kang18.12 %18.12%
  • Korea United Pharm Inc.11.98%
  • Duk-Young Kang10.58 %10.58%
  • United Foundation8.23%
  • Gui-Ja Kim0.3339 %0.33%

Share of the company, as of September 25, 2026

Leadership

  • Duk-Young Kang — Chief Executive Officer, 78

How much revenue does Korea United Pharm make?

Korea United Pharm reported 288.76 billion KRW in revenue for fiscal year 2025, about flat from 288.71 billion KRW in fiscal year 2024. In Q1 2026 revenue was 73.82 billion KRW.

What companies are similar to Korea United Pharm?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include AprilBio Co.,Ltd. (397030.KQ), HLB Pharmaceutical Co., Ltd. (047920.KQ), JW Holdings Corporation (096760.KS), Inventage Lab, Inc. (389470.KQ).

How has Korea United Pharm's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 221.04 billion KRW; FY2022, 262.52 billion KRW; FY2023, 278.94 billion KRW; FY2024, 288.71 billion KRW; FY2025, 288.76 billion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
FoundedDec 3, 1987
IPO DateOct 23, 2007
IPO StatusPublic
HeadquartersSeoul, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
Nonhyeon-ro 121street 22, Seoul
Phone
82 2 512 9981
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Korea United Pharm Inc. (033270.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/033270.KS

LinkedInLinkedInXXYouTubeYouTube